Syndax Pharmaceuticals (SNDX) News Today
SNDX fell 15.41% in the 10 minutes after this headline crossed at 16:01:07 ET on Monday, Oct 12:
Syndax Pharmaceuticals reported that axatilimab was well tolerated with no new safety concerns in the MaxPIRE trial.
Price 16.55 two minutes before the headline, 14.00 10 minutes after it.
Latest headline on this page:
1 headline on Syndax Pharmaceuticals appeared in our news feed in the last 7 days with a measured price reaction attached. 1 of them moved the underlying at least 0.35% in the minutes after the headline crossed. The largest measured reaction was -15.41% over 10 minutes on SNDX, after the headline at Oct 12, 16:01:07 ET.
What moved SNDX — last 7 days
| Time | Headline | 1 min | Reaction |
|---|---|---|---|
| Oct 12, 16:01:07 ET | Syndax Pharmaceuticals reported that axatilimab was well tolerated with no new safety concerns in the MaxPIRE trial.Volume 190.2K shares in 10 min | -21.27% | -15.41% · 10m |
Moves are measured against the price two minutes before each headline crossed, using validated 1-minute bars captured at publish time. A dash means no bar was available for that window. Reaction pending means the measuring window for that headline is still open. Not attributed means the headline does not name the company the move was measured on, so we hold the number back. Times are New York ET. Headlines appear here 1 minute after they cross the live tape.